2nd SOHO Italian Conference

http://www.sohoitaly.it/

 

2nd SOHO Italian Conference
M

TFR in CML: What Are the Influencing Factors? Do Patients Lose MR After Stopping TKIs? Can We Predict the Probability of Maintaining the TFR?

By 2nd SOHO Italian Conference FEATURING Michele Malagola
By 2nd SOHO Italian Conference FEATURING Michele Malagola
12 views
January 27, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison
Leukemia
14:51

MRD & ALL Management: What Role Does It Play in AlloHSCT Setting?

2nd SOHO Italian Conference

A. Rambaldi

25 views
17:00

How I Treat AML at MD Anderson: ATRA & GO Combos, Sequential HD Chem…

2nd SOHO Italian Conference

H. Kantarjian

195 views
09:43

MD Anderson Future Directions in AML: Efficacy of FLT3 / IDH Inhibit…

2nd SOHO Italian Conference

H. Kantarjian

303 views
10:02

How I Treat ALL at MD Anderson: What Hyper-CVAD Combinations Showed …

2nd SOHO Italian Conference

H. Kantarjian

30 views
13:11

MD Anderson Future Directions in ALL: How Effective Are New Blina/In…

2nd SOHO Italian Conference

H. Kantarjian

17 views
13:38

TFR and CML: Why Is TFR Important? What Happens After? Why Is It Dif…

2nd SOHO Italian Conference

E. Abruzzese

11 views
08:52

TFR in CML: What Are the Influencing Factors? Do Patients Lose MR Af…

2nd SOHO Italian Conference

M. Malagola

12 views
14:09

How I Treat Frontline CML: What Are the Differences in ELTS vs. Soka…

2nd SOHO Italian Conference

G. Saglio

16 views
09:15

Post-SCT Maintenance in AML: What Is the Role of Hypomethylating Age…

2nd SOHO Italian Conference

A. Sperotto

21 views
15:37

Allogenic Transplant in AML: How Does ASCT Compare to Chemo in Older…

2nd SOHO Italian Conference

A. Olivieri

18 views
13:56

MRD Assessment in Frontline AML: What Are the Characteristics of Dif…

2nd SOHO Italian Conference

F. Buccisano

21 views
09:22

Prognostic Relevance of BPDCN-Like Phenotype in Newly Diagnosed AML:…

2nd SOHO Italian Conference

R. Lemoli

21 views
11:45

Pro-Apoptotic Pathways in AML: How Does Venetoclax Work in Combinati…

2nd SOHO Italian Conference

S. Galimberti

10 views
14:40

Genomic Sequencing in AML and MDS: How Can We Define Subtypes and Mu…

2nd SOHO Italian Conference

I. Iacobucci

25 views
12:17

Novel mAbs in ALL: Is Ino Better than SoC? What Is the MRD-Negativit…

2nd SOHO Italian Conference

F. Lanza

11 views
10:44

mAbs in ALL: Does Blinatumomab Prolong Survival in R/R Ph+/- Disease…

2nd SOHO Italian Conference

C. Papayannidis

11 views
08:04

Cell Morphology in Acute Leukemias & Hematologic Malignancies: Diffe…

2nd SOHO Italian Conference

G. Zini

28 views
11:05

Synthetic Lethality Against ALL: How Often Is the Expression of DDR-…

2nd SOHO Italian Conference

A. Ghelli Luserna Di Rora

13 views
14:43

2020 SOHO Update on R/R ALL: Is CD19-Targeted CAR-T Beneficial for O…

2nd SOHO Italian Conference

J. Ribera

85 views
16:49

2020 SOHO Updates on ALL: Does Ponatinib+Steroids Help Induce CHR in…

2nd SOHO Italian Conference

G. Martinelli

138 views
11:57

2020 SOHO Updates on Newly Diagnosed AML: Does CPX-351 Increase OS a…

2nd SOHO Italian Conference

C. Cerchione

97 views
10:44

2020 SOHO Updates on AML: Is Targeting CAMDR a New Frontier? Can E-S…

2nd SOHO Italian Conference

C. Cerchione

90 views
18:18

MD Anderson State of the Art in CLL Treatment: What Is Changing and …

2nd SOHO Italian Conference

A. Ferrajoli

168 views
10:10

2020 SOHO Updates on Newly Diagnosed AML: What Is the ORR With Aza v…

2nd SOHO Italian Conference

A. de la Fuente

37 views
16:49

2020 SOHO Update on Ph-Like ALL: How Important Are Genomic Alteratio…

2nd SOHO Italian Conference

M. Konopleva

16 views
19:30

2020 SOHO Update on AML in Older Patients at MD Anderson: Therapy In…

2nd SOHO Italian Conference

T. Kadia

191 views
22:54

2020 SOHO Update on MPN: Ruxolitinib vs. BAT in ET, Ruxolitinib in P…

2nd SOHO Italian Conference

S. Verstovsek

24 views
18:07

2020 SOHO Update on Diagnostic Approaches to Ph-Like B-ALL: CRLF2 De…

2nd SOHO Italian Conference

S. Konoplev

10 views
09:51

2020 SOHO Update on FLT3+ AML: What Are the Novel FLT3 Inhibitors? H…

2nd SOHO Italian Conference

N. Daver

60 views
14:15

2020 SOHO Update on Immunotherapy in AML: Gemtuzumab Ozogamicin Plus…

2nd SOHO Italian Conference

N. Daver

122 views
16:36

How I Manage CML at MD Anderson in 2020: How Effective & Safe Is Das…

2nd SOHO Italian Conference

E. Jabbour

18 views
13:05

2020 SOHO Update on Frontline Therapy Optimization in ALL: How Effec…

2nd SOHO Italian Conference

E. Jabbour

19 views
10:43

2020 SOHO Update on Frontline MDS: What Is the Role of Genomic Annot…

2nd SOHO Italian Conference

G. Garcia-Manero

13 views
12:20

2020 SOHO Update on Antibodies in AML: Is Gemtuzumab Ozogamicin Effe…

2nd SOHO Italian Conference

F. Ravandi

15 views
12:54

2020 SOHO Update on Maintenance AML: Does It Improve Clinical Outcom…

2nd SOHO Italian Conference

F. Ravandi

15 views